Bristol-Myers Squibb (NYSE: BMY) beats Q2 2026 adjusted Non-GAAP EPS consensus of approx. $1.65 per share (July 30, 2026; confirmed by BMS press release)
Pending
✦ AI-generated prediction
Published on 27. July 2026
·
Predicted for 30. July 2026
·
Based on: Historical Cycle
BMS reports on July 30, 2026. Non-GAAP EPS consensus estimated at approximately $1.65 (extrapolated from Q1 2026 result and core product growth trajectory: Eliquis, Opdivo, Breyanzi). BMS has beaten EPS consensus for four consecutive quarters. Growing oncology pipeline (Opdualag, Camzyos, Breyanzi) offsets the fading Revlimid exclusivity tailwind. No Polymarket market; own estimate 60% (discount applied for consensus uncertainty).
Data basis for this prediction
- BMS Q2 2026 Earnings Date: 30. Juli 2026 (BMS Investor Relations, 27.07.2026)
- BMS: 4 aufeinanderfolgende EPS-Beats (Referenzwert Analystenberichte)
- Breyanzi Q1 2026 Umsatz: stark wachsendes CAR-T-Segment (BMS IR)
Note: This is an AI-generated statistical forecast for entertainment and information purposes. It does not constitute investment advice or a recommendation to buy or sell any financial instrument.
Verdict: Pending
This prediction is still open. It will be evaluated automatically against real-world sources after its due date.
📈 Economy
✦ AI
The ECB raised its deposit rate to 2.25% in June 2026 (first hike since 2023) and held on July 23, 2026 to assess Iran war inflation effects. ECB Chief Economist Philip Lane explicitly named September 10 as the 'next pivotal moment' for monetary policy (Bloomberg, July 24, 2026). Brent crude fell from above $100 to $90.28 (−8% on July 27, 2026) after US-Iran de-escalation, but remains well above the long-run equilibrium of ~$70. Eurostat Flash CPI July is published July 31; a reading ≥2.3% would add pressure. No dedicated Polymarket ECB September market; own estimate 52%, as the oil decline partially eases rate pressure.
📈 Economy
✦ AI
PayPal reports July 28, 2026 after market close. Non-GAAP EPS consensus is approximately $1.35 (extrapolated from Q1 2026 Non-GAAP EPS of ~$1.33 with expected 2–3% sequential growth). PayPal has beaten adjusted EPS consensus for eight consecutive quarters; ongoing restructuring (profitable core focus, Venmo monetisation, branded checkout improvements) supports margins. Brent's sharp drop to $90 (−8% on July 27 after US-Iran de-escalation) is a tailwind for travel and commerce transactions. No dedicated Polymarket market; calibrated at 68% based on eight-quarter beat history.
📈 Economy
✦ AI
Eli Lilly reports on August 5, 2026 before market open. The company is the global market leader in the GLP-1 segment (Mounjaro/Zepbound). Mounjaro quarterly revenues are growing continuously (~80% YoY); Lilly's new manufacturing facilities in North Carolina and Indiana have significantly reduced supply constraints since H2 2025. Lilly has beaten EPS consensus for five consecutive quarters and raised annual guidance four times. The Zepbound approval portfolio (obesity, heart failure) continues to expand. No Polymarket market; own estimate 79% based on structurally strong GLP-1 growth trajectory.